checkAd

     244  0 Kommentare USANA Health Sciences Reports Second Quarter 2019 Results

    USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 29, 2019.

    Financial Performance

    Second quarter 2019 net sales were $256.0 million, compared with $301.5 million in the prior-year period, or a 15.1% decrease year-over-year. The Company’s financial performance for the quarter was impacted, as noted in the pre-release of results on July 2, by the continuing challenging consumer environment in China. In addition, the strengthening of the U.S. dollar unfavorably impacted net sales by $12.4 million for the quarter. The Company’s total number of active customers at the end of the second quarter was 555,000, compared to 597,000 in the prior-year period.

    Second quarter net earnings were $21.4 million, or $0.91 per diluted share, compared with $33.9 million, or $1.36 per share during the prior-year period.

    “The continuing challenging market environment in China was the major factor that impacted our second quarter results,” said Kevin Guest, Chief Executive Officer. “During the second quarter, we offered promotions and incentives in China that have historically generated meaningful sales and customer growth. However, the contribution of these promotions was significantly lower than we anticipated, which we believe is due to the low consumer sentiment toward health products in China. We believe it could take several months for consumer sentiment and our momentum to improve in China. We remain optimistic in our long-term growth potential in this important market and our other markets around the world.”

    Regional Results

    Net sales in the Asia Pacific region decreased by 14.9% to $205.5 million for the second quarter of 2019. On a constant currency-basis, net sales in the Asia Pacific region decreased 10.1% during the second quarter of 2019. The total number of active customers in the Asia Pacific region decreased by 5.7% year-over-year. Within Asia Pacific, net sales:

    • Decreased 23.2% in Greater China (down 18.3% on a constant currency basis);
    • Decreased 1.5% in Southeast Asia Pacific (up 1.8% on a constant currency basis); and
    • Increased 18.9% in North Asia (up 28.0% on a constant currency basis).

    Active customers decreased by 12.3% in Greater China. In Southeast Asia Pacific and North Asia, Active customers increased by 2.9% and 27.0%, respectively.

    Net sales in the Americas and Europe region decreased by 15.6% to $50.5 million for the second quarter of 2019, primarily due to an 11.6% decrease in active customers.

    “We will continue to execute our 2019 strategy during the second half of the year, which includes introducing new products and planned promotional activity across our markets,” continued Mr. Guest. “We have tailored our plan to ensure that we have strategic offerings in the appropriate markets at the appropriate times to generate momentum in the business. Overall, we remain confident in the strategies we are pursuing for the long-term health of our business.”

    Share Repurchase Program Update

    During the quarter, the Company repurchased 367,800 shares of common stock for $27.6 million and ended with weighted average diluted shares outstanding of 23.4 million. The Company continues to have a strong balance sheet with no debt and $234.4 million in cash and short-term securities. As of June 29, 2019, there was $122.4 million remaining under the current share repurchase authorization.

    Outlook

    The Company reiterated the following consolidated net sales and earnings per share outlook for fiscal year 2019:

    • Consolidated net sales between $1.02 billion and $1.06 billion;
    • Earnings per share between $3.70 and $4.10.

    The Company’s outlook for the year reflects:

    • An estimated operating margin of between 11.9% and 12.7%;
    • An effective tax rate of approximately 34%;
    • An annualized diluted share count of approximately 22.7 million, which anticipates future share repurchase activity in 2019; and
    • An unfavorable impact on net sales of approximately $25 million related to a stronger U.S. dollar.

    Chief Financial Officer Doug Hekking commented, “Due to the lower-than-expected results in the first half of the year, we expect our operating margin for fiscal 2019 to be lower than our typical rate. While we are actively working to better align our cost structure with our sales performance, we plan to continue making the necessary investments to execute our long-term growth strategies.”

    Internal Investigation of China Operations

    As the Company first disclosed in February 2017, it is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. The investigation focuses on compliance with the Foreign Corrupt Practices Act and certain conduct and policies at BabyCare, including BabyCare’s expense reimbursement policies. The Audit Committee of the Company’s Board of Directors has assumed direct responsibility for reviewing these matters and has hired experienced counsel to conduct the investigation. While the Company does not believe that the subject amounts are quantitatively material, or will materially affect its financial statements, it cannot currently predict the outcome of the investigation on its business, results of operations, or financial condition. The Company’s internal investigation is substantially complete, however the Company continues to cooperate with the Securities and Exchange Commission and the United States Department of Justice. The Company cannot currently predict the duration, scope, or result of the investigation.

    Non-GAAP Financial Measures

    The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

    Conference Call

    The Company has posted the “Management Commentary, Results and Outlook” document on the Company’s website (http://ir.usana.com) under the “Investor Relations” section of the site. USANA will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, July 24, 2019 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, before moving directly into questions and answers.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: regulatory risk in China following the Chinese government’s 100-day review of the health product and direct selling industries; continued negative media coverage in China following the Chinese government’s 100-day review of these industries; global economic conditions generally; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and marketing activities; adverse publicity risks globally; risks associated with our international expansion and operations; and risks associated with the internal investigation into BabyCare’s operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

      USANA Health Sciences, Inc.
      Consolidated Statements of Operations
      (In thousands, except per share data)
      (Unaudited)
                       
          Quarter Ended   Six Months Ended
          30-Jun-18   29-Jun-19   30-Jun-18   29-Jun-19
                       
       Net sales   

     $    301,460

     

     $    256,016

     

     $    593,458

     

     $    529,006

       Cost of sales   

             49,991

     

             46,494

     

             99,366

     

             92,395

       Gross profit   

           251,469

     

           209,522

     

           494,092

     

           436,611

                       
       Operating expenses                 
       Associate incentives   

           132,790

     

           111,511

     

           262,152

     

           234,041

       Selling, general and administrative   

             67,537

     

             66,854

     

           137,669

     

           136,409

                       
       Earnings from operations   

             51,142

     

             31,157

     

             94,271

     

             66,161

                       
       Other income   

                  388

     

               1,355

     

               1,250

     

               2,645

       Earnings before income taxes   

             51,530

     

             32,512

     

             95,521

     

             68,806

                       
       Income taxes   

             17,623

     

             11,134

     

             32,668

     

             23,256

                       
       NET EARNINGS   

     $      33,907

     

     $      21,378

     

     $      62,853

     

     $      45,550

                       
                       
       Earnings per share - diluted   

     $          1.36

     

     $          0.91

     

     $          2.56

     

     $          1.93

       Weighted average shares outstanding - diluted   

             24,841

     

             23,370

     

             24,557

     

             23,648

    USANA Health Sciences, Inc.

    Consolidated Balance Sheets
    (In thousands)
     
    As of As of

    ASSETS

    29-Dec-18 29-Jun-19

    Current Assets

    (Unaudited)

    Cash and cash equivalents

    $

    214,326

    $

    231,353

    Securities held-to-maturity, net

     

    63,539

     

    2,999

    Inventories

     

    81,948

     

    88,127

    Prepaid expenses and other current assets

     

    32,522

     

    26,304

    Total current assets

     

    392,335

     

    348,783

     

    Property and equipment, net

     

    92,025

     

    92,637

    Goodwill

     

    16,815

     

    16,829

    Intangible assets, net

     

    31,811

     

    31,129

    Deferred income taxes

     

    3,348

     

    5,473

    Other assets

     

    18,129

     

    37,550

    Total assets

    $

    554,463

    $

    532,401

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current Liabilities

    Accounts payable

    $

    9,947

    $

    11,694

    Other current liabilities

     

    138,739

     

    117,065

    Total current liabilities

     

    148,686

     

    128,759

     

    Deferred income taxes

     

    13,367

     

    5,787

    Other long-term liabilities

     

    1,264

     

    13,699

     

    Stockholders' equity

     

    391,146

     

    384,156

    Total liabilities and stockholders' equity

    $

    554,463

    $

    532,401

     
    USANA Health Sciences, Inc.

    Sales by Region

    (unaudited)

    (in thousands)

     

    Quarter Ended

     

     

     

     

     

    30-Jun-18

    29-Jun-19

    Change from prior
    year

    Currency
    impact on
    sales

    % change
    excluding
    currency
    impact

     
    Asia Pacific
    Greater China

    $

    167,841

    55.6

    %

    $

    128,946

    50.3

    %

    $

    (38,895

    )

    (23.2

    %)

    $

    (8,170

    )

    (18.3

    %)

    Southeast Asia Pacific

     

    54,771

    18.2

    %

     

    53,960

    21.1

    %

     

    (811

    )

    (1.5

    %)

     

    (1,818

    )

    1.8

    %

    North Asia

     

    18,986

    6.3

    %

     

    22,575

    8.8

    %

     

    3,589

     

    18.9

    %

     

    (1,731

    )

    28.0

    %

    Asia Pacific Total

     

    241,598

    80.1

    %

     

    205,481

    80.2

    %

     

    (36,117

    )

    (14.9

    %)

     

    (11,719

    )

    (10.1

    %)

     
    Americas and Europe

     

    59,862

    19.9

    %

     

    50,535

    19.8

    %

     

    (9,327

    )

    (15.6

    %)

     

    (659

    )

    (14.5

    %)

     

    $

    301,460

    100.0

    %

    $

    256,016

    100.0

    %

    $

    (45,444

    )

    (15.1

    %)

    $

    (12,378

    )

    (11.0

    %)

     

    Active Associates by Region(1)

    (unaudited)

     

     

     

    As of

     

     

    30-Jun-18

     

    29-Jun-19

     
    Asia Pacific
    Greater China

    111,000

    38.0

    %

    102,000

    35.8

    %

    Southeast Asia Pacific

    85,000

    29.1

    %

    87,000

    30.5

    %

    North Asia

    26,000

    8.9

    %

    33,000

    11.6

    %

    Asia Pacific Total

    222,000

    76.0

    %

    222,000

    77.9

    %

     
    Americas and Europe

    70,000

    24.0

    %

    63,000

    22.1

    %

     

    292,000

    100.0

    %

    285,000

    100.0

    %

    Active Preferred Customers by Region (2)

    (unaudited)

     

     

     

    As of

     

     

    30-Jun-18

     

    29-Jun-19

    Asia Pacific
    Greater China

    206,000

    67.5%

    176,000

    65.2%

    Southeast Asia Pacific

    20,000

    6.6%

    21,000

    7.7%

    North Asia

    11,000

    3.6%

    14,000

    5.2%

    Asia Pacific Total

    237,000

    77.7%

    211,000

    78.1%

     
    Americas and Europe

    68,000

    22.3%

    59,000

    21.9%

     

    305,000

    100.0%

    270,000

    100.0%

    (1)

    Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2)

    Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

     




    Business Wire (engl.)
    0 Follower
    Autor folgen

    USANA Health Sciences Reports Second Quarter 2019 Results USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 29, 2019. Financial Performance Second quarter 2019 net sales were $256.0 million, compared with $301.5 million in the prior-year …